IL17A and myeloid sarcoma: In CD4+ T-cells, separated from blood samples from 11 untreated and 12 IFN-β-treated MS patients (sub-study 2 population), we measured mRNA-expression levels of: the TH1 markers TBX1, HLX1, EOMES and IFNG (Fig. 2A); the TH17 markers RORC and IL17A (Fig. 2B); the TH2 markers GATA3 and IL4 (Fig. 2C); TNF (Fig. 2D); and the TREG markers FOXP3, IL10 and TGFB1 (Fig. 2E).